ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by Lynx9on Jun 21, 2018 11:54pm

62 Views

Post# 28210585

RE:Voting over the Phone

Just reading the bullboards and I too have not received any proxy in the mail, nor do I have a control number to vote on line. Where did most of you get your control number from? Mail, email or on line?
Seems odd to me that I have not received anything, at least nothing that I have found, in the mail for what seems, after reading a few past posts, a very important proxy vote.

Bullboard Posts

Morning Market Outlook for Nov. 14, 2024